CompoundedGuide
FDA-approved product exists

Semaglutide

FDA-approved

Semaglutide has FDA-approved prescription products (OZEMPIC (NDA209637), OZEMPIC / RYBELSUS (NDA213051), RYBELSUS (NDA213182), WEGOVY (NDA218316), WEGOVY / WEGOVY FLEXTOUCH / WEGOVY HD (NDA215256)). FDA's drug shortage database lists 3 Semaglutide entries (To Be Discontinued) as of 2026-07-25; that describes supply of an approved product, not whether compounding is lawful. Semaglutide is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 50 registered ClinicalTrials.gov studies cite Semaglutide (25 completed, 12 recruiting, 6 not yet recruiting, 3 active not recruiting, 2 enrolling by invitation, 2 unknown); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.

What we've verified

Product status
FDA-approved: OZEMPIC (NDA209637), OZEMPIC / RYBELSUS (NDA213051), RYBELSUS (NDA213182), WEGOVY (NDA218316), WEGOVY / WEGOVY FLEXTOUCH / WEGOVY HD (NDA215256)
Still checking
Compounding status, shortage status, safety signals

Verified sources

Research and evidence

FDA-approved product exists cite Semaglutide. Registration is not evidence of approval, efficacy, or safety.

Browse every trial and publication for Semaglutide →

For developers
JSON record Markdown Source packet